Get the Stockscreener App
2.95
1.72%
0.05
After Hours:
2.84
-0.11
-3.73%
Traws Pharma Inc stock is traded at $2.95, with a volume of 194.98K.
It is up +1.72% in the last 24 hours and up +54.45% over the past month.
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.
See More
Previous Close:
$2.90
Open:
$2.89
24h Volume:
194.98K
Relative Volume:
1.32
Market Cap:
$20.84M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+18.00%
1M Performance:
+54.45%
6M Performance:
+39.15%
1Y Performance:
-41.11%
1-Day Range:
$2.70
$2.96
1-Week Range:
$2.4204
$3.265
52-Week Range:
$0.97
$19.44
Traws Pharma Inc Stock (TRAW) Company Profile
Name
Traws Pharma Inc
Sector
Industry
Phone
267-759-3680
Address
12 PENNS TRAIL, NEWTOWN
Compare TRAW with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TRAW
Traws Pharma Inc
|
2.95 | 20.66M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Traws Pharma Inc Stock (TRAW) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-22 | Initiated | Ladenburg Thalmann | Buy |
| May-18-21 | Initiated | Guggenheim | Buy |
| Mar-01-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-17-18 | Downgrade | Maxim Group | Buy → Hold |
| Oct-09-17 | Initiated | H.C. Wainwright | Buy |
| Apr-27-17 | Initiated | Laidlaw | Buy |
| Jul-01-15 | Upgrade | Piper Jaffray | Neutral → Overweight |
| May-05-15 | Initiated | H.C. Wainwright | Buy |
View All
Traws Pharma Inc Stock (TRAW) Latest News
Forecasting Traws Pharma Inc. price range with options dataJuly 2025 Sector Moves & Low Risk High Win Rate Stock Picks - newser.com
Tick level data insight on Traws Pharma Inc. volatilityRisk Management & Consistent Income Trade Recommendations - newser.com
Traws Pharma (TRAW) Initiates Trials for New COVID-19 Treatment - GuruFocus
Traws Pharma begins phase 2 trials of ritonavir-free COVID treatment - Investing.com India
Trend analysis for Traws Pharma Inc. this weekJuly 2025 Momentum & Free High Return Stock Watch Alerts - newser.com
Traws Pharma Doses First Patient with Ratutrelvir in Phase 2 COVID Studies, Expects Results by Year-End 2025 - GlobeNewswire
Traws Pharma, Inc. Doses First Patient in Phase 2 COVID Study - TradingView
Using fundamentals and technicals on Traws Pharma Inc.2025 Investor Takeaways & Safe Capital Growth Stock Tips - newser.com
Using portfolio simulators with Traws Pharma Inc. included2025 Trading Recap & Stock Portfolio Risk Control - newser.com
Live market analysis of Traws Pharma Inc.2025 Trading Volume Trends & Stock Timing and Entry Methods - newser.com
Analyzing drawdowns of Traws Pharma Inc. with statistical toolsWeekly Trend Report & AI Driven Stock Price Forecasts - newser.com
Is Traws Pharma Inc. stock safe for conservative investorsForecast Cut & High Win Rate Trade Alerts - newser.com
Technical signs of recovery in Traws Pharma Inc.Market Activity Recap & Long-Term Growth Portfolio Plans - newser.com
Will Traws Pharma Inc. stock benefit from green energy trendsJuly 2025 Momentum & Short-Term High Return Strategies - newser.com
Key metrics from Traws Pharma Inc.’s quarterly data2025 Market Overview & Fast Exit/Entry Strategy Plans - newser.com
Traws Pharma Appoints Dr. John Leaman to Board, Confirms CEO and CFO Roles - MyChesCo
Ranking Traws Pharma Inc. among high performing stocks via tools2025 Market WrapUp & Growth Focused Stock Reports - newser.com
Why analysts recommend Traws Pharma Inc. (0T20) stock2025 Short Interest & Daily Profit Focused Screening - newser.com
Is Traws Pharma Inc. (0T20) stock attractive post correction2025 Support & Resistance & Short-Term High Return Ideas - newser.com
Traws Pharma Announces Promising Clinical Data for Rigosertib in Rare Cancer - MSN
Will Traws Pharma Inc. (0T20) stock extend growth storyEarnings Growth Summary & Real-Time Chart Breakout Alerts - newser.com
Why Traws Pharma Inc. (0T20) stock is a must watch ticker2025 Historical Comparison & Risk Managed Trade Strategies - newser.com
Market reaction to Traws Pharma Inc.’s recent newsMarket Trend Summary & Daily Stock Trend Reports - newser.com
[DEF 14A] Traws Pharma, Inc. Definitive Proxy Statement - Stock Titan
Traws Pharma Inc 0T20 Stock Analysis and ForecastStock Price Forecasts & Free Get High Impact Recommendations - earlytimes.in
Traws Pharma Appoints New Independent Director and CEO - The Globe and Mail
Traws Pharma, Inc. Appoints Iain Dukes as Chief Executive Officer - MarketScreener
Traws Pharma, Inc. Appoints Charles Parker as Chief Financial Officer - MarketScreener
Reversal indicators forming on Traws Pharma Inc. stockTrade Performance Summary & AI Enhanced Trading Alerts - newser.com
Traws Pharma appoints John Leaman to board, removes interim tags from execs - Investing.com
Traws Pharma Appoints John Leaman, MD, as Director - citybiz
Traws Pharma, Inc. Appoints John Leaman, MD, to Board of Directors and Officially Names Key Executives as CEO and CFO - Quiver Quantitative
Traws Pharma Adds John Leaman, MD, as Independent Director and Formalizes Appointments of Two Key Executives - The Manila Times
D pipelineStock Surge & Reliable Momentum Entry Alerts - newser.com
Using data tools to time your Traws Pharma Inc. exitChart Signals & Consistent Profit Alerts - newser.com
Traws Pharma Inc Stock (TRAW) Financials Data
There is no financial data for Traws Pharma Inc (TRAW). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.15%
1.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):